Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naive type 2 diabetic patients.

ABSTRACT:

Background

The weight-reducing effect of exenatide has been proved, but too much weight loss in normal-weight patients may concern physicians. This study evaluated the effects of exenatide monotherapy on glycemic control and weight change in normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes (T2D).

Methods

In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks. The primary efficacy endpoint was the effect of baseline body mass index (BMI) on glycemic control, measured as the change in HbA1c from baseline to Week 48 compared among different BMI groups. Other endpoints included comparisons of the effects of exenatide on fasting

SUBMITTER: Deng H 

PROVIDER: S-EPMC6850147 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature